Geneva, Nov. 3 -- International Clinical Trials Registry received information related to the study (ACTRN12625001160426) titled 'Personalised Risk Assessment and Infection Surveillance with Disease Modifying Therapies (PRISM) - A prospective registry and biorepository' on Oct. 23.
Study Type: Observational
Study Design:
Purpose: Screening
Duration: Longitudinal
Selection: Defined population
Timing: Both
Primary Sponsor: The University of Melbourne
Condition:
Infection
Autoimmune Conditions
Infection
Autoimmune Conditions
Infection - Studies of infection and infectious agents
Inflammatory and Immune System - Autoimmune diseases
Intervention:
Patients with auto-immune diseases receiving, or planning to receive, disease modifying t...